Dietary of Inflammatory bowel disease (IBD)
Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine. Diet can play a role in tackling the symptoms.
Several pre-clinical studies1-3 have explored the potential relationship between dietary supplementation with bovine casein glycomacropeptide (CGMP) and its impact on supporting the dietary management of IBD.
At Arla Foods Ingredients, we are continuously exploring the potential benefits of Lacprodan® CGMP-20 , a unique ingredient with a high content of casein glycomacropeptide, that has proven safe to be used within dietary management of IBD4.A versatile, palatable ingredient with a high purity, Lacprodan® CGMP-20, can be used in different types of medical nutrition applications such as UHT drinks, bars and powders.
Check our white paper, where we dive into the scientific research surrounding Lacprodan® CGMP-20.
Read more about casein glycomacropeptide (CGMP).
References:
- López-Posadas, R., et al., Bovine glycomacropeptide has intestinal antiinflammatory effects in rats with dextran sulfate-induced colitis. J Nutr, 2010. 140(11): p. 2014-9.
- Requena, P., et al., Bovine glycomacropeptide ameliorates experimental rat ileitis by mechanisms involving downregulation of interleukin 17. British Journal of Pharmacology, 2008. 154(4): p. 825-832.
- Ortega-González, M., et al., Validation of bovine glycomacropeptide as an intestinal anti-inflammatory nutraceutical in the lymphocyte-transfer model of colitis. British Journal of Nutrition, 2014. 111(7): p. 1202-1212.
- Hvas, C.L., et al., Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study. Eur J Clin Invest, 2016. 46(6): p. 555-63.
